Mood stabilizer prescriptions, which were previously only used for certain illnesses like bipolar disorder, have alarmingly increased in recent years. The use of mood stabilizers like lithium, valproate, and lamotrigine has increased as mental health diagnoses become more common and awareness of psychiatric disorders grows, despite ongoing concerns about their long-term effectiveness and side effects.
Mood stabilizers have been praised for many years as a vital tool for treating mood disorders. However, given that doctors are increasingly using these drugs as first-line treatments for ailments for which they may not be necessary, some experts are starting to wonder if these drugs are being overprescribed.
| Aspect | Details |
|---|---|
| Common Mood Stabilizers | Lithium, Valproate, Lamotrigine |
| Prescription Trends | Mood stabilizers down from 62% to 26% (1997-2016) |
| Concerns | Antipsychotics increasing, long-term cognitive effects with lithium |
| Alternative Treatments | CBT, IPT gaining popularity over medication |
| Source | https://pmc.ncbi.nlm.nih.gov/, https://www.bmj.com/ |
According to a recent study by Yale University’s Dr. Samuel T. Wilkinson, the percentage of bipolar disorder patients taking mood stabilizers has dramatically dropped over the previous 20 years. Instead, antipsychotic drugs like quetiapine and aripiprazole are now prescribed to a greater number of patients, frequently without the use of mood stabilizers.
For several reasons, the trend is alarming. Although second-generation antipsychotics have been successful in treating bipolar disorder’s manic episodes, prolonged use of these medications raises concerns about potential side effects, such as tardive dyskinesia, a movement disorder, and metabolic syndrome, which includes obesity and diabetes.
“The shift toward antipsychotic medications may be driven by aggressive marketing campaigns and the convenience of newer medications, but there’s a lack of comparative effectiveness data showing that these drugs are better than mood stabilizers in managing bipolar disorder,” according to Dr. Wilkinson.
For a long time, mood stabilizers—especially lithium—have been regarded as the most effective way to treat bipolar disorder. Lithium is still the most thoroughly studied mood stabilizer and has been demonstrated to lower the risk of suicidality in bipolar disorder patients. Its advantages in lowering the frequency and intensity of mood swings cannot be disregarded, despite the possibility of adverse effects ranging from thyroid problems to kidney dysfunction.
However, the number of mood stabilizer prescriptions has drastically decreased in recent years. Mood stabilizer use for bipolar disorder decreased from 62% of cases to just 26% between 1997 and 2016, according to a study based on outpatient visits. Second-generation antipsychotic prescriptions, on the other hand, have increased dramatically from 12% to 51%. These patterns point to a fundamental change in psychiatric care, with a focus on newer drugs that might not be as effective for every patient.
Leading psychiatrist Dr. Andrew Nierenberg of Massachusetts General Hospital contends that using mood stabilizers excessively may be harmful. “While mood stabilizers are effective for some patients, especially those with bipolar I disorder, we must be careful not to over-prescribe them for conditions like generalized anxiety or unipolar depression,” according to him. In fact, research has demonstrated that antidepressants, which are frequently prescribed without a mood stabilizer in place, can exacerbate bipolar disorder by causing manic episodes in patients.
Patient demand and doctors’ comfort with tried-and-true treatments frequently put pressure on doctors to prescribe drugs like mood stabilizers. In mental health care, there is a noticeable trend toward using medications to treat mood disorders, sometimes at the expense of alternative therapeutic approaches. Given the lengthy wait times for therapy, doctors may be more likely to prescribe medications, which provide faster results, to patients who want immediate relief from their symptoms. But this strategy may result in a long-term reliance on drugs that aren’t always the best option for each patient.
It’s also important to consider the dangers of long-term mood stabilizer use, especially in terms of cognitive side effects. Patients who have been taking lithium for long periods of time frequently complain of fatigue, memory loss, and cognitive dysfunction. Additionally, patients who need to have their blood checked frequently for lithium toxicity may find the procedure difficult, which may result in irregular use.
However, lithium is not the only substance being investigated. There are additional issues with other mood stabilizers, such as lamotrigine and valproate. For instance, lamotrigine, although generally better tolerated, may result in a rare but severe skin rash that can be fatal, whereas valproate has been associated with weight gain and liver toxicity.
What is the answer, then? A more individualized approach to treatment that considers each patient’s unique needs and preferences is being advocated by some experts. “It’s important to recognize that not all mood disorders require mood stabilizers, and patients should be monitored closely to ensure that they are receiving the best treatment for their condition,” says Dr. Wilkinson.
A more balanced approach is gaining traction in the face of an increase in prescriptions. Psychotherapy should once again be the main course of treatment, according to some psychiatrists, with drugs acting as a supplement rather than the first line of defense. Compared to pharmaceutical treatments, cognitive-behavioral therapy (CBT), interpersonal therapy (IPT), and other talk therapies have demonstrated efficacy in treating mood disorders while posing fewer long-term risks.
Mood stabilizers will undoubtedly continue to be a mainstay in the treatment of bipolar disorder as the debate rages on. Their widespread use should be carefully considered, though. Mental health professionals can better serve their patients without succumbing to overmedication by emphasizing individualized care, cutting back on overprescription, and implementing non-pharmacological therapies.